A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Capsaicin (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Centrexion Therapeutics
  • Most Recent Events

    • 08 Nov 2017 Results assessing safety and efficacy presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 30 Oct 2017 According to a Centrexion Therapeutics media release, 12-week data from this trial will be presented at the American College of Rheumatology and the Association of Rheumatology Health Professionals' (ACR/ARHP) 2017 Annual Meeting.
    • 20 Jul 2017 Results from this trial will be presented at the American Podiatric Medical Association's (APMA) 2017 Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top